Peptides DB

Research-centric peptide and protocol reference hub

CJC-1295 vs LL-37

Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team

CJC-1295: Research use — not FDA-approvedLL-37: Research use — not FDA-approved

A data-driven comparison of CJC-1295 and LL-37 (also searched as LL-37 vs CJC-1295) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.

Verdict

CJC-1295 centers on muscle, while LL-37 leans toward healing. On indexed research, LL-37 is ahead (CJC-1295: 4 studies, Preclinical; LL-37: 5, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.

Key takeaways

  • CJC-1295 is strongest for muscle; LL-37 for healing.
  • Evidence: CJC-1295 Preclinical (4 studies) vs LL-37 Human evidence (5).
  • Both are research-use compounds — not FDA-approved.

Effect profiles, overlaid

HealingMuscleMetabolicNeuroSleepInflammationSkin
CJC-1295LL-37

At a glance

CJC-1295Preclinical
Strongest: MuscleStudies: 4Level:
LL-37Human evidence

Human Cathelicidin | Antimicrobial Peptide

Strongest: HealingStudies: 5Level: Well Studied

CJC-1295 vs LL-37: side-by-side

MetricCJC-1295LL-37
ClassImmune
Regulatory statusResearch use onlyResearch use only
Evidence gradePreclinicalHuman evidence
Studies indexed45
Research levelWell Studied
Strongest effectMuscle & body compHealing & recovery
Healing & recovery2.05.0
Muscle & body comp4.00.0
Metabolic & appetite3.00.0
Neuro & mood2.00.0
Sleep & circadian3.00.0
Inflammation & immune1.04.0
Skin & aesthetics1.00.0

▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).

Mechanism & pharmacokinetics

PropertyCJC-1295LL-37
MechanismGHRH (1–29) analog, modified
RouteSubcutaneous injection
Half-life~30 min

Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.

What is CJC-1295?

GHRH analogue used in research contexts for GH/IGF-1 modulation, muscle and bone density, sleep, and recovery.

Full CJC-1295 profile, mechanism & studies →

What is LL-37?

### LL-37 Summary LL-37 is a human cathelicidin antimicrobial peptide that plays a crucial role in the innate immune response, exhibiting antimicrobial, immunomodulatory, and wound healing properties. Its diverse functions make it a subject of interest in various fields of biomedical research.

Full LL-37 profile, mechanism & studies →

Which is better for your goal?

GoalBetter fitWhy
HealingLL-375.0/5 effect signal
MuscleCJC-12954.0/5 effect signal
MetabolicCJC-12953.0/5 effect signal
NeuroCJC-12952.0/5 effect signal
SleepCJC-12953.0/5 effect signal
InflammationLL-374.0/5 effect signal
SkinCJC-12951.0/5 effect signal

Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.

Can you stack CJC-1295 and LL-37?

People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.

CJC-1295 vs LL-37: side effects

CJC-1295

No community-reported effects logged yet.

LL-37

No community-reported effects logged yet.

Anonymous community reports (count = number of reports), not clinical incidence rates.

What the research says

CJC-1295 has 4 approved studies indexed (Preclinical), and LL-37 has 5 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.

Frequently asked questions

Is CJC-1295 or LL-37 better?

It depends on your goal. CJC-1295 is strongest for muscle; LL-37 for healing. LL-37 has more indexed studies (5). See the goal-by-goal breakdown above.

Is CJC-1295 or LL-37 better for weight loss?

CJC-1295 shows the stronger metabolic & appetite profile (3.0/5) in community effect data — though weight-loss outcomes depend on the individual and the evidence base.

Is CJC-1295 or LL-37 better for muscle?

CJC-1295 leads on the muscle & body-composition axis (4.0/5).

Which has more research, CJC-1295 or LL-37?

CJC-1295 has 4 approved studies indexed (Preclinical); LL-37 has 5 (Human evidence). Higher counts mean more to read, not proven superiority.

Can you stack CJC-1295 and LL-37?

Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.

What are the side effects of CJC-1295 vs LL-37?

CJC-1295: no community-reported effects logged yet. LL-37: none logged yet. These are anonymous reports, not incidence rates — see each profile.

Is CJC-1295 or LL-37 FDA-approved?

CJC-1295 is a research-use compound and is not FDA-approved. LL-37 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.

Is LL-37 better than CJC-1295?

For healing, LL-37 has the edge; for muscle, CJC-1295 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.

Comparing related peptides

Regulatory & legal status

CJC-1295 and LL-37 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.